First Oral Therapy Targeting ESR1 Mutations Approved

Orserdu (elacestrant), developed by Stemline Therapeutics, a subsidiary of the Italian Menarini Group, has received final FDA approval. Orserdu is the first and only oral selective estrogen receptor degrader (SERD) indicated for patients with estrogen receptor-positive (ER+), HER2-negative, and ESR1-mutated locally advanced or metastatic breast cancer. Previously, the only second-line treatment option for metastatic breast cancer was an injectable drug like fulvestrant. With the approval of Orserdu, patients now have a convenient oral administration option. This represents a significant advancement, offering a new precision medicine-based treatment standard for patients who have developed resistance after CDK4/6 inhibitor therapy.

Superior Efficacy Demonstrated in Phase 3 EMERALD Study

The basis for this FDA approval is the results of the EMERALD study, a Phase 3 clinical trial involving 477 patients. The clinical results showed that, in patients with ESR1-mutated breast cancer, Orserdu reduced the risk of disease progression or death by 45% compared to standard endocrine therapy (SOC, fulvestrant or an aromatase inhibitor) (Hazard Ratio = 0.55; 95% CI: 0.39, 0.77). In particular, the median progression-free survival (mPFS) in the Orserdu group was 3.8 months, compared to 1.9 months in the control group, clearly demonstrating statistically significant clinical efficacy. Adverse reactions were mostly mild to moderate nausea and fatigue, suggesting that long-term patient compliance will also be significantly improved.

Financial Value of Licensing and Strategic Partnerships

Originally, Orserdu was a compound developed by Radius Health, but in July 2020, the Menarini Group entered into a licensing agreement to secure global exclusive rights. This deal consisted of an upfront payment of $30 million (USD$30,000,000) and up to $320 million (USD$320,000,000) in future commercialization and development milestones, along with a royalty rate in the low-to-mid teens on net sales. Subsequently, the Menarini Group acquired Stemline Therapeutics, taking over commercialization in the United States. Radius Health then sold a portion of these royalty rights to DRI Healthcare Trust for $130 million, securing early cash flow through a strategic move.

Targeting the $800 Million Metastatic Breast Cancer Market

The U.S. market for ESR1-mutated metastatic breast cancer treatment is estimated at approximately $800 million in 2022, and is expected to grow at a high annual rate of 9.6%. Since up to 40% of patients with ER+/HER2- metastatic breast cancer acquire ESR1 mutations after CDK4/6 inhibitor therapy, the penetration rate of Orserdu, which targets these mutations, is expected to be rapid. While competitors such as AstraZeneca's camizestrant and Roche's giredestrant are in late-stage clinical trials, Orserdu has a first-mover advantage and is well-positioned to solidify its market dominance.